Long-term remission of small cell lung cancer after reactivation of tuberculosis following immune-checkpoint blockade: A case report

被引：7
|
作者：
Sirgiovanni, Mattia [1 ,2 ]
Hinterleitner, Clemens [1 ,2 ]
Horger, Marius [3 ]
Atique, Naushad Bijoy [1 ,2 ]
Lauer, Ulrich M. [1 ,2 ]
Zender, Lars [1 ,2 ,4 ]
Hinterleitner, Martina [1 ,2 ]
机构：
[1] Univ Hosp Tuebingen, Dept Med Oncol & Pneumol, Tubingen, Germany
[2] Univ Tubingen, Cluster Excellence iFIT EXC Image Guided & Functi, Tubingen, Germany
[3] Univ Hosp Tuebingen, Dept Diagnost & Intervent Radiol, Tubingen, Germany
[4] German Canc Res Ctr, German Canc Res Consortium DKTK, Partner Site Tuebingen, Heidelberg, Germany
来源：
THORACIC CANCER | 2021年 / 12卷 / 05期
关键词：
immune-checkpoint inhibitors; lung cancer; PD-L1; tuberculosis;
D O I：
10.1111/1759-7714.13821
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Immune-checkpoint inhibitors (ICIs) provide a promising treatment option for advanced tumors including small cell lung cancer (SCLC). Nevertheless, in addition to immune-related adverse events (irAEs), an increased risk of infection including tuberculosis has been previously described. Here, we report a case of long-term remission of a patient with SCLC after reactivation of lung tuberculosis following ICI therapy. Our case illustrates the complexity of ICI-associated immune modulation in tuberculosis. Since new lesions in lung cancer patients are commonly associated with tumor progression, infections with mycobacterial tuberculosis may be underdiagnosed in lung cancer.
引用
收藏
页码：699 / 702
页数：4
相关论文
共 50 条
  • [21] Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges
    Mountzios, Giannis
    Remon, Jordi
    Hendriks, Lizza E. L.
    Garcia-Campelo, Rosario
    Rolfo, Christian
    Van Schil, Paul
    Forde, Patrick M.
    Besse, Benjamin
    Subbiah, Vivek
    Reck, Martin
    Soria, Jean-Charles
    Peters, Solange
    NATURE REVIEWS CLINICAL ONCOLOGY, 2023, 20 (10) : 664 - 677
  • [22] Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer
    Chae, Young Kwang
    Pan, Alan
    Davis, Andrew A.
    Mohindra, Nisha
    Matsangou, Maria
    Villaflor, Victoria
    Giles, Francis
    CLINICAL LUNG CANCER, 2017, 18 (02) : 132 - 140
  • [23] Long-term outcomes in extensive disease small cell lung cancer patients treated without immune checkpoint inhibitors
    Wakuda, Kazushige
    Yabe, Michitoshi
    Kodama, Hiroaki
    Nishioka, Naoya
    Miyawaki, Taichi
    Miyawaki, Eriko
    Mamesaya, Nobuaki
    Kobayashi, Haruki
    Omori, Shota
    Ono, Akira
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Murakami, Haruyasu
    Shimizu, Tetsuo
    Gon, Yasuhiro
    Takahashi, Toshiaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (12) : 1736 - 1743
  • [24] Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer
    Frigola, Joan
    Navarro, Alejandro
    Carbonell, Caterina
    Callejo, Ana
    Iranzo, Patricia
    Cedres, Susana
    Martinez-Marti, Alex
    Pardo, Nuria
    Saoudi-Gonzalez, Nadia
    Martinez, Debora
    Jimenez, Jose
    Sansano, Irene
    Mancuso, Francesco M.
    Nuciforo, Paolo
    Montuenga, Luis M.
    Sanchez-Cespedes, Montse
    Prat, Aleix
    Vivancos, Ana
    Felip, Enriqueta
    Amat, Ramon
    MOLECULAR ONCOLOGY, 2021, 15 (04) : 887 - 900
  • [25] Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
    Giannis Mountzios
    Jordi Remon
    Lizza E. L. Hendriks
    Rosario García-Campelo
    Christian Rolfo
    Paul Van Schil
    Patrick M. Forde
    Benjamin Besse
    Vivek Subbiah
    Martin Reck
    Jean-Charles Soria
    Solange Peters
    Nature Reviews Clinical Oncology, 2023, 20 : 664 - 677
  • [26] Long-term survival in metastatic small-cell lung cancer (SCLC). A case report
    Gruen, A.
    Schultze, J.
    Kimmig, B.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2009, 185 : 102 - 102
  • [27] Comprehensive transcriptomic analysis of acquired resistance after immune-checkpoint inhibitors in non-small cell lung cancer
    Joe, Cheol Yong
    Bang, Yeong Hak
    Park, Sehhoon
    Jung, Hyun Ae
    Sun, Jong-Mu
    Choi, Yoon-La
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Lee, Se-Hoon
    CANCER RESEARCH, 2024, 84 (06)
  • [28] Long-term survival after combination therapy with atezolizumab in a patient with small-cell lung cancer: a case report
    Gao, Guangbin
    Wu, Yajing
    Liu, Qing
    Zhai, Chang
    Inoue, Yusuke
    Zhang, Xinyuan
    Lv, Xiaoyan
    Zhang, Wei
    Wang, Jun
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (12) : 3795 - 3806
  • [29] Bringing immune-checkpoint inhibitors earlier in the management of non-small cell lung cancer
    Borgeaud, Maxime
    Friedlaender, Alex
    Addeo, Alfredo
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (11) : 2353 - 2358
  • [30] Salvage extended surgery after immune-checkpoint inhibitor treatment for advanced non-small cell lung cancer
    Goto, Eisuke
    Hattori, Aritoshi
    Fukui, Mariko
    Matsunaga, Takeshi
    Takamochi, Kazuya
    Suzuki, Kenji
    SURGERY TODAY, 2024, 54 (08) : 917 - 926
12345